tbuckley/cabot-search huggingface dataset:
MNGI-09. HISTOPATHOLOGIC FEATURES PREDICT LOCAL CONTROL AFTER ADJUVANT RADIOTHERAPY FOR ATYPICAL MENINGIOMA
Authors: William Chen, Stephen Magill, Ashley Wu, Harish Vasudevan, Manish Aghi, Philip Theodosopoulos, Arie Perry, Michael McDermott, Penny Sneed, Steve Braunstein, David Raleigh
Journal: Neuro-Oncology (2017)

To evaluate outcomes following primary surgical resection of atypical meningioma with or without adjuvant radiotherapy. One-hundred eighty-two patients who underwent primary resection of atypical meningioma from 1993 to 2014 were retrospectively identified. Patient, tumor and histopathologic data were extracted from the medical record and compared using multivariate Cox proportional hazards models and recursive partitioning analysis (RPA). Median age and imaging follow-up were 57 years and 4.4 years, respectively. Gross total resection (GTR) was achieved in 114 cases (63%), and 42 patients (23%) received adjuvant radiotherapy. Prognostic factors for death from any cause included GTR (RR 0.4, 95% CI 0.1-0.9, P=0.02) and MIB1 labeling index (LI) ≤7% (RR 0.4, 95% CI 0.1-0.9, P=0.04). Local control at 5 years was 82% with radiotherapy versus 65% without radiotherapy. Prognostic factors for local progression included GTR (RR 0.2, 95% CI 0.1-0.5, P=0.002), radiotherapy (RR 0.2, 95% CI 0.1-0.4, P<0.001) and MIB1 LI ≤7% (RR 0.2, 95% CI 0.1-0.5, P<0.001). After subtotal resection, radiotherapy (RR 0.3, 95% CI 0.1-0.9, P=0.04) and <6 mitoses per 10 high power fields (RR 0.2, 95% CI 0.05-0.6, P=0.006) were predictive for local progression. After GTR, radiotherapy (0 of 10 irradiated tumors recurred, P=0.02) and MIB1 LI ≤7% (RR 0.1, 95% CI 0.003-0.3, P=0.001) were predictive for local progression. After GTR without radiotherapy, 2.2% of meningiomas with MIB1 LI ≤7% recurred (1 of 45), compared to 38% with MIB1 LI >7% (13 of 34; P<0.001). RPA confirmed the existence of a high-risk GTR cohort without radiotherapy and MIB1 LI >7%. Adjuvant radiotherapy improves local control of atypical meningioma irrespective of extent of resection. Although independent validation is required, MIB1 labeling index may be a useful guide to select patients for adjuvant radiotherapy of atypical meningioma after gross total resection.
La légionellose associée au voyage chez des touristes européens en Espagne
Authors: A Galmés Truyols, J. F. Martinez Navarro
Journal: Eurosurveillance (1997)

Depuis la deuxieme moitie des annees 1980, la legionellose associee au voyage est devenue preoccupante pour les pays europeens en raison de la morbidite dans la population europeenne ; de plus, l'apparition de cas chez les touristes constitue une menace pour l'economie des pays mediterraneens. En consequence, le groupe de travail europeen sur les infections a Legionella (EWGLI : European Working Group for Legionella Infections) (1) a ete cree en 1986, coordonne jusqu'en 1993 par le Laboratoire National de Bacteriologie a Stockholm puis par le Public Health Laboratory Service, Communicable Disease Surveillance Centre, a Londres. Les pays de residence des patients transmettent les declarations de cas aux pays qu'ils ont visites.
MA 05.03 The Early Monitoring of Derived Neutrophil-To Lymphocyte Ratio (dNLR) Could Be a Surrogate Marker of Benefit of Immunotherapy in NSCLC
Authors: L. Mezquita, E. Auclin, M. Charrier, R. Ferrara, C. Caramella, D. Planchard, S. Ponce, L. Paz-Ares, C. Audigier-Valette, L. Tessonnier, G. Martinez, G. Zalcman, J. Lahmar, J. Remon, J. Adam, N. Chaput, J. Soria, B. Besse
Journal: Journal of Thoracic Oncology (2017)
SCDT-26. STEM CELL LOADED ONCOLYTIC VIRUSES TRACK AND KILL METASTATIC BRAIN TUMORS
Authors: Khalid Shah, Wanlu Du, David Fisher
Journal: Neuro-Oncology (2017)

Brain metastatic patients have multiple metastatic lesions or diagnostically challenging asymptomatic lesions, making surgery an inadequate therapeutic option. Oncolytic viruses (OV) that selectively replicate in tumor cells are an emerging modality of cancer treatment that have shown promising results in both preclinical studies and clinical trials. However, issues related to OV delivery via the bloodstream, such as virus neutralization, sequestration, and inefficient extravasation, pose major barriers to the development of OV-based therapies for brain metastasis. We have armed mesenchymal stem cells (MSC) with oncolytic herpes virus (oHSV) variants (MSC-oHSV) and tested them in different mouse models of brain metastatic tumor derived from patient derived brain seeking metastatic tumor cells from melanomas, breast and lung tumors. We show that intracarotid artery administration of MSC-oHSV, but not of purified oHSV alone, effectively tracks metastatic tumor lesions and significantly prolongs the survival of brain tumor bearing mice. We also show that a combination of MSC-oHSV and PD-L1 blockade increases IFNγ-producing CD8+ tumor-infiltrating T lymphocytes and results in a profound extension of the median survival in syngeneic brain metastatic mouse models. These findings provide a clinically applicable therapeutic platform to target disseminated metastatic lesions in the brain.
Perplexing Conclusions Concerning Heat-Not-Burn Tobacco Cigarettes
Authors: Serge Maeder, Manuel C. Peitsch
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
IMMU-52. SELECTION OF GLIOMA T-CELL THERAPY TARGETS BASED ON THE ANALYSIS OF TUMOR IMMUNOPEPTIDOME AND EXPRESSION PROFILES
Authors: Diego Carrera, Josie Hayes, Soeren Mueller, Samuel J Shelton, Toni Weinschenk, Colette Song, Jens Fritsche, Oliver Schoor, Sabrina Kuttruff-Coqui, Norbert Hilf, Gary Kohanbash, Payal Watchmaker, Michael C Oldham, Joseph Costello, Harpreet Singh, Hideho Okada
Journal: Neuro-Oncology (2017)

Diffuse infiltrating low-grade gliomas (WHO grade II or III) are slow-growing primary brain tumors, but are considered malignant due to their invasive growth with a high risk of recurrence and progression to higher-grade tumors. While novel immunotherapeutic approaches are being developed, the paucity of well-characterized antigens that can be safely targeted remains a challenge; this led us to conduct an extensive evaluation searching for targetable T-cell epitopes in gliomas. In the current study, we report our analysis on a set of 64 glioma-associated antigens. Initial screening was based on the presentation of at least one of their epitopes by human leukocyte antigen (HLA)-A*0201 or A*2401 in primary glioblastoma tissue, their oncogenic role as proteins in glioma-genesis and their capability of inducing an antigen-specific T-cell response in human peripheral blood samples. Furthermore, we assessed differential expression of these epitopes in 39 primary gliomas paired with their corresponding recurrent tumors, and then evaluated datasets containing RNA expression levels for normal brain and other organs. As a result, we found 5 antigen epitopes being exclusively expressed in all WHO grade II gliomas, with even higher expression in their corresponding recurrent tumors, without significant levels measured in normal brain or peripheral organs. Our results strongly suggest that immunotherapy targeting these epitopes can be highly glioma-specific and safe, reducing the likelihood of adverse events such as on-target, off-tumor toxicity. These results are especially significant given the marked heterogeneity of gene and protein expression in gliomas. Moreover, our methods can be applied to increase the rate of discovery for neoantigens and naturally-occurring epitopes in this and other types of tumors.
Virus respiratorios y síndromes gripales : una encuesta en la región de Roma, invierno de 2004-2005
Authors: G Rezza, C Valdarchi, S Puzelli, M Ciotti, F Farchi, C Fabiani, L Calzoletti, I Donatelli, C F Perno
Journal: Eurosurveillance (2006)

La informacion disponible sobre la etiologia viral de los sindromes gripales (SG) en los paises del sur de Europa es escasa. Aqui describimos los principales resultados de una investigacion llevada a cabo en la region de Roma durante el invierno de 2004-2005. 
La definicion de caso de sindrome gripal fue: fiebre superior a 37,5 °C con al menos un sintoma constitucional y un sintoma respiratorio, descrito durante el periodo de la encuesta. El virus de la gripe y los otros virus respiratorios se identificaron por PCR en muestras faringeas. Se recogieron los datos individuales basicos en un formulario estandar. 
De los 173 casos de sindromes gripales de la encuesta, 74 dieron positivo para un virus, y dos para dos virus. En total, el 33,5% de los casos eran positivos para los virus influenza, 5,2% para los adenovirus, 3,5% para los virus parainfluenza, 1,7% para los coronavirus y 1,2% para el virus respiratorio sincitial. La proporcion de virus gripales detectados fue mas elevada durante el periodo de « alta actividad gripal ». La distribucion de los agentes virales variaba segun los grupos de edad, siendo mas frecuentes los virus influenza en los jovenes. 
En menos del 50% de los casos de SG se identificaron patogenos virales durante la temporada gripal activa. La deteccion de virus distintos a los virus influenza fue esporadica, sin poder ser identificados grandes brotes debidos a agentes especificos.
RTHP-09. DIFFUSION TENSOR IMAGING DRIVEN GROWTH MODELING FOR TARGET DEFINITION IN GLIOBLASTOMA
Authors: Jesper Foldsted Kallehauge, Trine Lignell Guldberg, Anja Harbøll, Morten Bjørn Jensen, Slávka Lukacova
Journal: Neuro-Oncology (2017)

The Clinical Target Volume (CTV) is routinely based on contrast enhanced T1w (+Gd) and T2 FLAIR MRI sequences. Both T1 and T2 FLAIR have been shown to over- or underestimate the microscopic spread. The growth characteristics of gliomas favor spread of tumor cells along the white matter fiber tracts with reduced infiltration in grey matter. Tumor growth models incorporating the diffusion tensors (DTI) allow to account more consistently for the glioma growth. The aim of the study was to investigate the potential of DTI driven growth model for target definition in glioblastoma. Eleven GBM patients were scanned using T1w, T2 FLAIR, T1w+Gd and DTI. The brain was segmented into white matter, grey matter and cerebrospinal fluid. The Fisher-Kolmogorov growth model was used assuming uniform proliferation and difference in white and grey matter diffusion of a factor 10. The tensor directionality was tested using an anisotropy weighting parameter of zero (γ0) and twenty (γ20). The volumetric comparison was performed using Hausdorff distance, Dice similarity coefficient (DSC) and surface area using one-tailed paired Student’s t-test with a significance level of 0.05. The median standard CTV was 180 cm3. The median surface area for the standard CTV was 211 cm2. The median surface area of respective CTVγ0 and CTVγ20 significantly increased to 338 cm2 and 376 cm2. The Hausdorff distance was greater than zero and significantly increased for both CTVγ0 and CTVγ20 with respective median of 18.7mm and 25.2mm. The DSC for both CTVγ0 and CTVγ20 were significantly below one with respective median of 0.74 and 0.72, which means that 74% and 72% of standard CTV were included in CTVγ0 and CTVγ20, respectively. DTI driven growth models result in more irregular shapes with a significant increased surface area and decreased overlap between the standard and model derived volume.
Detección de las amenazas debidas a enfermedades infecciosas en los Países Bajos : el comité de alerta rápida
Authors: J C Rahamat-Langendoen, J A van Vliet, A Wm Suijkerbuijk
Journal: Eurosurveillance (2006)

En los Paises Bajos se establecio un comite de alerta rapida para detectar a tiempo y de modo exhaustivo las amenazas para la salud publica debidas a enfermedades infecciosas. El articulo describe los resultados de una evaluacion retrospectiva y descriptiva de la exhaustividad de los eventos detectados por este comite. 
La informacion sobre los brotes de enfermedades infecciosas en los Paises Bajos en 2002 y 2003 descritos en la Revista holandesa de medicina (Nederlands Tijdschrift voor Geneeskunde), asi como los eventos ligados a enfermedades infecciosas en otros Paises se compararon con los informes de las reuniones semanales del comite de alerta rapida holandes. Si un brote o evento ocurrido en el extranjero no se habia mencionado en las reuniones del comite de alerta, se debia explicar ese olvido. Para eventos en otros paises, estos eran mencionados o no en las reuniones del comite, en funcion de constituir o no una amenaza para la salud publica en los Paises Bajos. 
Todos los brotes de enfermedades infecciosas en los Paises Bajos, publicados o mencionados en la Revista holandesa de medicina, fueron discutidos en el comite de alerta. Sin embargo, tres eventos ocurridos en otros paises en 2002 no habian sido discutidos por el comite, aunque hubieran debido serlo, segun los criterios descritos previamente. Dichos eventos son el brote de gripe aviar A/H5N1 en gallos domesticos en Hong Kong, el aumento de portadores de microorganismos productores de beta-lactamasas de amplio espectro en pacientes hospitalizados en Escocia, y brotes de sarampion en varios paises. En 2003, el comite discutio acerca de todos los eventos ocurridos en otros paises que pudieran ser una amenaza para los Paises Bajos. 
En 2002 y 2003, el comite de alerta rapida detecto practicamente todas las amenazas debidas a enfermedades infecciosas y brotes de enfermedades infecciosas con un impacto nacional publicados en varias fuentes de la literatura.
NIMG-12. CAN F-DOPA PET DIFFERENTIATE GLIOMA-RECURRENCE FROM TREATMENT-RELATED CHANGES?
Authors: Tadeja Urbanic Purkart, Franz Payer
Journal: Neuro-Oncology (2017)

In glioma therapy differentiating tumor progression from treatment related changes such as pseudoprogression and radionecrosis is crucial. However, there are no simple reliable tools to distinguish between such modalities. In unclear cases on the conventional MRI-imaging PET with amino acid analogues has been proposed to be a promising adjunctive method. 18F-DOPA PET has the advantage of high tracer uptake in the brain tissue and low in non-neoplastic tissue. We performed a retrospective analysis of 54 patients (28 woman, 26 men) with a history of glioma treated between 2011 and 2014 in our department. All patients showed changes on MRI suggestive for recurrence, progression of glioma or treatment- related changes such as pseudoprogression or radionecrosis. Diagnosis of tumor recurrence/progression was confirmed by histological examination after surgery or by subsequent clinical course based on neurological symptoms and findings on follow-up MRI. 18F-DOPA scans were obtained with a high resolution scanner (Siemens). Tumor to contralateral normal cortex ratios (T/N) were determined by region-of interest analysis. Results were correlated with histopathological findings or, in cases without surgery, with clinical course and MRI findings. Fifty four glioma patients with median age of 52,5 years (range 21-85) underwent this retrospective 18F-DOPA PET analysis. Analysed were 37 patients with HGG and 17 with LGG. Histopathologic analysis revealed radio- or chemotherapy induced changes without evidence of vital tumor in 5 of 54 cases. Three other cases were considered to have necrosis based on neurological symptoms and findings on follow-up MRI. Twenty nine (n= 29) patients exhibited tumor recurrence/progression. There was a significant statistical difference (p=0.005) between recurrence of high-grade glioma and necrosis. The uptake of 18F -DOPA in high-grade glioma was higher than in low-grade glioma, the difference was however not significant. No statistical significant difference in 18F-DOPA ratio was determined between low-grade glioma and necrosis.
P3.02-014 Amplicon-Based Next-Generation Sequencing (NGS) of Plasma Cell-Free DNA (cfDNA) for Detection of Driver and Resistance Mutations in NSCLC
Authors: N. Guibert, Y. Hu, N. Feeney, E. Michael, S. Woodhouse, K. Howarth, G. Jones, C. Paweletz, G. Oxnard
Journal: Journal of Thoracic Oncology (2017)
ATIM-20. CLINICAL OUTCOMES WITH IPILIMUMAB IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH RECENTLY DIAGNOSED GLIOBLASTOMA - A RETROSPECTIVE COHORT REVIEW
Authors: Nicholas Brown, Thomas Carter, Denise Cohn-Brown, Paul Mulholland
Journal: Neuro-Oncology (2017)

Median survival for patients with glioblastoma remains under a year. Whilst there is accumulating interest in the role of checkpoint inhibitors in newly diagnosed glioblastoma, the results of clinical trials are awaited to establish clinical efficacy. We have previously presented clinical outcomes in patients with relapsed glioblastoma treated with the anti-CTLA-4 monoclonal antibody ipilimumab in combination with the anti-VEGF monoclonal antibody bevacizumab. We retrospectively identified patients with newly diagnosed WHO grade IV glioma who received treatment with ipilimumab and bevacizumab at our centre between March 2015 and March 2017. Baseline demographics, tumour characteristics, concurrent therapy, radiological responses, and survival data were analysed. Nineteen patients were identified, 18 with glioblastoma and one with a glioneuronal tumour (Grade IV). Median age was 52 years (range 22–85) and 79% were male. 5% (1/19) had an IDH mutation, and 38% (6/16) had MGMT promotor methylation. Ipilimumab (3mg/kg, 3 weekly, 4 cycles) and bevacizumab (10mg/kg 2 weekly), given with concurrent G-CSF or GM-CSF were commenced after radiotherapy (except in one patient who did not receive radiotherapy). 58% of patients had prior surgical debulking (42% biopsy only), 79% had prior radical radiotherapy with concomitant temozolomide, 16% had short course radiotherapy, and 5% did not receive radiotherapy. 84% of patients received adjuvant temozolomide, and 89% received concurrent valganciclovir. In those with visible disease on pre-treatment MRI, 62% (8/13) had a radiological response. At time of analysis, 63% of patients remained alive, and 58% were alive and progression free. Median follow up was 15 months. Median survival in patients who had had debulking surgery was 23 months, and median survival in those who had a biopsy only was 16 months. This combination requires prospective evaluation in clinical trials to formally determine efficacy. Data on this cohort continues to be collected and will be updated.
SURG-10. CONVECTION ENHANCED DELIVERY OF TOPOTECAN AND GADOLINIUM FOR RECURRENT GBM VIA THE CLEVELAND MULTIPORT CATHETER: A FIRST IN HUMAN STUDY
Authors: Michael Vogelbaum, Alireza Mohammadi, Cathy Brewer, David M Peereboom, Manmeet Ahluwalia
Journal: Neuro-Oncology (2017)

Convection enhanced delivery (CED) was developed as a technique to bypass barriers to effective treatment of gliomas. The Cleveland Multiport Catheter (CMC) is a novel device that was designed to produce high volume, backflow resistant CED. We have investigated the ability of the CMC to deliver a chemotherapy and tracer to enhancing and non-enhancing regions of recurrent high grade gliomas. A Sponsor-Investigator IND covered both the CMC and drug (topotecan HCl with gadolinium DTPA). Two pilot trials were opened: the first trial evaluated delivery in both enhancing tumor and tumor-infiltrated brain, and the second trial evaluated delivery in tumor-infiltrated brain after resection of the enhancing tumor. We used MRI to evaluate the distribution of the infused gadolinium to evaluate efficacy of drug delivery. Quantitative assessment of drug distribution was made by a blinded evaluator. Twelve patients have been treated to date. All patients underwent successful placement of two CMCs each and completed infusions ranging from 48 to 96 hours; 3 in the first pilot trial and 9 in the second trial. Intraoperative and peri-operative MRIs demonstrated tracer delivery from every CMC placed to date (24 catheters, 96 microcatheters) without obvious backflow along the CMC shaft. We found large differences in the volumes of distribution between catheters placed in enhancing versus nonenhancing, tumor infiltrated brain, with high volumes of distribution (range: 25 to 92 cc) observed in the patients whose treatment focused on tumor infiltrated brain. There were no hemorrhages related to catheter placement or removal. Infusion related safety data will be presented. The CMC consistently provides high volume, backflow resistant CED in tumor infiltrated brain. Co-infusion of a tracer is an essential tool for understanding the delivery characteristics of any CED device. Safety of CED appears to be primarily related to drug concentration and distribution.
P1.03-054 A Phase II Randomized Trial of Gefitinib Alone vs Olaparib Plus Gegitinib in Advanced NSCLC EGFRmut + Goal Trial Spanish Lung Cancer Group
Authors: B. Massuti, R. García Campelo, O. Arrieta, D. Rodríguez-Abreu, A.L. Ortega Granados, M. Majem, D. Vicente Baz, P. Lianes, J. Bosch Barrera, A. Insa, M. Domine, N. Reguart, M. Guirado, M. Sala, S. Vazquez, R. Bernabe, J.A. Macias, R. Palmero, A. Verdu, A. Drozdowskyj, R. Rosell
Journal: Journal of Thoracic Oncology (2017)
Efficacy and safety of immune checkpoint inhibitor nivolumab and radiotherapy combination in advanced NSCLC
Authors: L. Belluomini, F. Fiorica, A. Stefanelli, A. Santini, B. Urbini, F. Daniel, L.R. Martella, I. Toma, F. Lancia, A. Moretti, E. Bannò, C. Giorgi, A. Frassoldati
Journal: Annals of Oncology (2017)
P2.07-049 Early Clinical Predictors of Progressive Disease or Non-Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
Authors: R. Kumar, M. Brandao, N. Joharatnam, J. Pealing, D. Walder, A. Minchom, C. Milner-Watts, S.Y. Moorcraft, F. Turkes, N. Yousaf, J. Bhosle, S. Popat, M. O’Brien
Journal: Journal of Thoracic Oncology (2017)
P2.13-002 The LungScreen WA Project: Feasibility of LDCT Screening with the PLCOm2012 Risk Model and PanCan Nodule Risk Calculator
Authors: K.P. Lim, D. Manners, B. Adler, S. Melsom, E. Harris, F. Brims, A. Mcwilliams
Journal: Journal of Thoracic Oncology (2017)